Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1177/1756286418785502 http://scihub22266oqcxt.onion/10.1177/1756286418785502 C6048670!6048670!30034538     free     free     free       Ther+Adv+Neurol+Disord 2018 ; 11 (ä): ä Nephropedia Template TP {{tp|p=30034538|t=2018. New developments in brain metastases |pdf=|usr=}}{{30034538}} gab.com Text New developments in brain metastases JO: Ther Adv Neurol Disord http://www.kidney.de/pget.php?&tw=1&pmid=30034538 #FOAvip Patients with brain metastases (BM) are a population of high clinical need for new therapeutic approaches due to, as yet, very impaired survival prognosis. However, only few clinical trials have specifically addressed this prognostically highly heterogeneous patient population. New developments in the treatment of BM patients aim to reduce the side effects of local therapies, for example, by redefining the indications for stereotactic radiosurgery and whole-brain radiotherapy (WBRT) or introducing new applications like hippocampal sparing WBRT. Furthermore, systemic therapies become a more important treatment approach in patients harboring targetable mutations, as recent BM-specific endpoints in several phase III trials have shown promising intracranial efficacy. In addition, immune-checkpoint inhibitors show promising intracranial efficacy, particularly in patients with melanoma and non-small lung cancer BM. Here, we provide a review on the recent new developments in the local and systemic therapy approaches in BM patients. Twit Text FOAVip New developments in brain metastases ????Ther Adv Neurol Disord http://www.kidney.de/pget.php?&tw=1&pmid=30034538 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=30034538 #FOAvip English Wikipedia <ref>{{Cite pmid|30034538}}</ref> New developments in brain metastases #MMPMID30034538 Berghoff AS; Preusser M Ther Adv Neurol Disord 2018[]; 11 (ä): ä PMID30034538show ga Patients with brain metastases (BM) are a population of high clinical need for new therapeutic approaches due to, as yet, very impaired survival prognosis. However, only few clinical trials have specifically addressed this prognostically highly heterogeneous patient population. New developments in the treatment of BM patients aim to reduce the side effects of local therapies, for example, by redefining the indications for stereotactic radiosurgery and whole-brain radiotherapy (WBRT) or introducing new applications like hippocampal sparing WBRT. Furthermore, systemic therapies become a more important treatment approach in patients harboring targetable mutations, as recent BM-specific endpoints in several phase III trials have shown promising intracranial efficacy. In addition, immune-checkpoint inhibitors show promising intracranial efficacy, particularly in patients with melanoma and non-small lung cancer BM. Here, we provide a review on the recent new developments in the local and systemic therapy approaches in BM patients. äNew developments in brain metastases (epmc).pdf DeepDyve Pubget Overpricing